# Tamsulosin

## Harnalidge OCAS 0.4mg prolonged release

| 藥物代碼 | OHAR4 |
| :--- | :--- |
| 適應症 | Treatment of signs and symptoms of benign prostatic hyperplasia \(BPH\) |
| 副作用 | Cardiovascular: Orthostatic hypotension \(6% to 19%\) Central nervous system: Headache \(19% to 21%\), dizziness \(15% to 17%\) Genitourinary: Abnormal ejaculation \(8% to 18%\) Respiratory: Rhinitis \(13% to 18%\)Miscellaneous: Infection \(9% to 11%\) |
| 禁忌 | Hypersensitivity to tamsulosin or any component of the formulation |
| 藥物保存方式 | 室溫 |
| 用法用量 | Dosing: Adult ---Benign prostatic hyperplasia \(BPH\): Males: Oral: 0.4 mg once daily ~30 minutes after the same meal each day; dose may be increased after 2 to 4 weeks to 0.8 mg once daily in patients who fail to respond. If therapy is discontinued or interrupted for several days, restart with 0.4 mg once daily. ---Bladder outlet obstruction symptoms \(unlabeled use\): Oral: 0.4 mg once daily ---Ureteral stones, expulsion \(unlabeled use\): Oral: 0.4 mg once daily, discontinue after successful expulsion \(average time to expulsion was 1 to 2 weeks\). Note: Patients with stones &gt;10 mm were excluded from studies. |
| 肝功能異常 | 無需調整劑量  輕度至中度肝功能不全的患者無須調整劑量 重度肝功能不全患者不建議使用 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 可能安全 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

